Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Subscribe To Our Newsletter & Stay Updated
